Abstract
Melittin, a phospholipase A2 activator, induces two-phase changes in the contractility of isolated rat papillary muscle. The first phase is characterized by an increase in the force of muscle contraction during the first 5–15 min of perfusion, the increase being the greatest at 0.4 μg/ml melittin. This phase is abolished by 10 μM indomethacin. In the second phase, dose-dependent inhibition of muscle contraction reaches the maximum after 30–45 min of perfusion and is abolished by the lipoxygenase inhibitor nordihydroguaiaretic acid (10 μM).
Similar content being viewed by others
References
K. R. Chien, A. Han, A. Sen,et al., Circ. Res.,54, 313–322 (1984).
P. B. Corr, R. W. Cross, and B. E. Sobel,Circ. Res.,55, 135–154 (1984).
M. M. Couttenye, N. M. De Clerck, A. G. Herman, and D. L. Brutsaert,J. Cardiovasc. Pharmacol.,7, No. 5, 971–976 (1985).
M. Endoh,Eur. J. Pharmacol.,39, 259–265 (1976).
A. N. Fonteh, D. A. Bass, L. A. Marshall,et al., J. Immunol.,152, No. 11, 5438–5446 (1994).
T. Kuzuya, S. Hoshida, Y. Kim,et al., Cardiovasc. Res.,27, 1056–1060 (1993).
H. Oe, T. Kuzuya, S. Hoshida,et al., Am. J. Physiol.,267, H1396-H1402 (1994).
F. Oudot, A. Grynberg, and J. P. Sergiel,Am. J. Physiol.,268, H308-H315 (1995).
D. W. Schwertz and J. Halverson.Basic Res. Cardiol.,87, 113–127 (1992).
W. T. Shier,Proc. Natl. Acad. Sci. USA,76, 195–199 (1979).
D. W. Snyder, W. A. Crafford, J. L. Glashow,et al., Am. J. Physiol.,241, H700-H707 (1981).
S. Sugiyama, M. Hayakawa, S. Nagai,et al., Life Sci.,40, No. 3, 225–231 (1987).
W. Warbanow,Acta Biol. Med. Germ.,35, 1167–1168 (1976).
A. Zalewski, S. Goldberg, and P. R. Maroko,Int. J. Cardiol.,21, No. 26, 247–257 (1988).
Author information
Authors and Affiliations
Additional information
Translated fromByulleten' Eksperimental'noi Biologii i Meditsiny, Vol. 124, No. 7, pp. 25–27, July, 1997
Rights and permissions
About this article
Cite this article
Brovkovich, V.M., Moibenko, A.A. Effect of melittin on the contractility of rat papillary muscle. Bull Exp Biol Med 124, 642–644 (1997). https://doi.org/10.1007/BF02445049
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02445049